Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

Delayed Quote. Delayed  - 08/30 04:42:43 pm
24.14 USD   +0.84%
02:08p IMPAX LABORATOR : Provides Update on Epinephrine Injection, USP Auto..
08/29 Mylan to launch generic EpiPen at half the price of original
08/29 IMPAX LABORATOR : Issues Voluntary, Nationwide Recall for One Lot of..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
02:08p IMPAX LABORATORIES : Provides Update on Epinephrine Injection, USP Auto-Injector
08/29 Mylan to launch generic EpiPen at half the price of original
08/29 IMPAX LABORATORIES : Issues Voluntary, Nationwide Recall for One Lot of Lamotrig..
08/27 IMPAX LABORATORIES : Issues Voluntary, Nationwide Recall for One Lot of Lamotrig..
08/27 IMPAX LABORATORIES, INC. : Issues Voluntary, Nationwide Recall for One Lot of La..
08/22 IMPAX LABORATORIES INC : Change in Directors or Principal Officers, Amendments t..
08/22 IMPAX LABORATORIES : Richard A. Bierly Appointed to Impax Laboratories Board of ..
08/18 IMPAX LABORATORIES : Reports Second Quarter 2016 Financial Results
08/09 IMPAX LABORATORIES : Management's Discussion and Analysis of Results of Operatio..
08/09 IMPAX LABORATORIES : Reports Second Quarter 2016 Financial Results
More news
Sector news : Pharmaceuticals - NEC
04:01pDJOrexigen in Canadian Marketing Pact With Valeant for Diet Drug
08:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06:59a OPKO Health Is A Buy At $9 - Cramer's Lightning Round (8/29/16)
08/29 EPIPEN : Facts Versus Opinion; With Cost-Benefit Analysis
08/25 Shocked! Mylan, Biotechs Swoon After Hillary's Statement
08/09 Impax Laboratories (IPXL) George Frederick Wilkinson on Q2 2016 Results - Ear..
08/09 Midday Gainers /Losers
Advertisement
Financials ($)
Sales 2016 915 M
EBIT 2016 191 M
Net income 2016 86,8 M
Debt 2016 448 M
Yield 2016 -
P/E ratio 2016 43,61
P/E ratio 2017 11,70
EV / Sales 2016 2,42x
EV / Sales 2017 2,02x
Capitalization 1 768 M
More Financials
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Full-screen chart
Technical analysis trends IMPAX LABORATORIE...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 29,2 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George Frederick Wilkinson President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Vishal K. Gupta CSO, Senior Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC-44.01%1 768
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
NOVARTIS AG-10.83%208 887
MERCK & CO., INC.19.29%174 236
More Results